Amlodipine‒folic acid combo reduces BP, homocysteine in patients with H-type hypertension

20 hours ago
Amlodipine‒folic acid combo reduces BP, homocysteine in patients with H-type hypertension

Combination therapy with amlodipine and folic acid demonstrates greater efficacy in lowering both blood pressure (BP) and plasma homocysteine (Hcy) compared with amlodipine alone in patients with elevated plasma Hcy (≥10 μmol/l) and hypertension, defined as H-type hypertension, according to a study.

A total of 299 men and 141 women were randomized to receive amlodipine 5 mg (control, group A), amlodipine 5 mg plus folic acid 0.4 mg (group B), or amlodipine plus folic acid 0.8 mg (group C). All participants were followed at 2, 4, 6, and 8 weeks.

Groups B and C demonstrated significantly greater efficacy in reducing both BP and Hcy compared with group A at 4 weeks. This benefit was sustained at the end of week 8 (group B vs A: 31.7 percent vs 6.1 percent; p<0.001; group C vs A: 32.8 percent vs 6.1 percent; p<0.001).

Similarly, both groups B and C were more efficacious in lower Hcy and increasing folate levels than amlodipine monotherapy at 8 weeks. No significant difference was observed in BP lowering and adverse events across the three treatment groups.

“The efficacy of BP lowering and safety profile were comparable among the three treatment groups,” according to the authors.

“H-type hypertension can synergistically increase the risk of cardiovascular diseases, especially for stroke,” they said.

J Hypertens 2026;44:2217-2226